Developer docs
API playgroundTry for free, no card

Search company profiles

DotBio

Full company profile

uuid0002d4s

Namestring
DotBio
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multifunctional antibodies, antibody therapeutics, cancer immunotherapy, biopharmaceutical research, monoclonal antibodies
Industry2 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
No data
Revenue model1 record
1Biopharmaceutical Development
TypeSubscription Recurring
Description

Pre-revenue biopharmaceutical company developing multifunctional antibody therapeutics. Revenue model not yet established as company is in early research and development stage following recent pre-Series A funding.

bioworld.com
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

DotBio develops multi-functional antibodies based on its proprietary DotBody technology as next-generation cancer therapies. The Singapore-based biopharmaceutical company engineers antibody candidates designed to engage multiple therapeutic targets simultaneously, addressing complex diseases through its preclinical antibody pipeline.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

DotBio is a Singapore-based biopharmaceutical company focused on developing multifunctional antibodies. The company raised $5.6 million in a pre-Series A funding round in 2023 to support its research and development efforts. No specific named products or modules were identified in the available sources.

Product and service1 record
1DotBody Multifunctional Antibody Pipeline
CategoryBiopharmaceutical Therapeutics
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Genmab is a leading antibody therapeutics company and the developer of the DuoBody bispecific antibody platform, making it a direct strategic reference point for DotBio's DotBody multifunctional antibody approach.

TypeDirect peer
Description

Zymeworks develops multifunctional and bispecific antibody therapeutics using its proprietary platforms (e.g., Azymetric), closely paralleling DotBio's DotBody-based multifunctional antibody strategy in oncology.

TypeDirect peer
Description

AbCellera is an antibody discovery and engineering platform company building multispecific candidates, representing a comparable platform-based business model to DotBio's DotBody technology.

TypeDirect peer
Description

Akeso is an Asia-based biopharmaceutical company with a leading pipeline of bispecific and multispecific antibody oncology drugs, making it a strong geographic and modality peer for DotBio.

5Dragonfly Therapeutics
TypeDirect peer
Description

Dragonfly is developing multispecific antibody-based therapeutics (e.g., its TriNKET platform) for cancer and immune diseases, a close functional analogue to DotBio's multifunctional antibody focus.

TypeEmerging player
Description

Adagene is an Asia-headquartered (China/Singapore) clinical-stage biotech developing antibody-based therapeutics including bispecifics, an emerging regional peer with comparable modality and geography to DotBio.

TypeEmerging player
Description

Cullinan Oncology is a clinical-stage oncology company developing bispecific antibodies and immune-engaging therapeutics, comparable as a smaller oncology-focused biologics developer.

8Atreca
TypeEmerging player
Description

Atreca develops antibody-based therapeutics using a proprietary immune repertoire platform, comparable to DotBio as a platform-driven antibody discovery company in oncology.

TypeOthers
Description

WuXi Biologics is a leading Asia-based biologics contract development and manufacturing organization that supports bispecific/multispecific antibody developers like DotBio with discovery, manufacturing, and IND-enabling services.

TypeBroad incumbent
Description

Innovent is a leading Chinese biopharmaceutical company with a portfolio that includes bispecific antibodies (e.g., PD-1-based bispecifics), representing an established Asia-based peer with overlap in multifunctional oncology biologics.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DotBio

Biopharmaceutical Therapeuticsdotbiopharma.com

DotBio firmographics

Firmographics
Name
DotBio
Website
https://dotbiopharma.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

DotBio industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Multifunctional antibodies
  • Antibody therapeutics
  • Cancer immunotherapy
  • Biopharmaceutical research
  • Monoclonal antibodies

Where DotBio is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices1 record

Markets served

DotBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Biopharmaceutical Development: Pre-revenue biopharmaceutical company developing multifunctional antibody therapeutics. Revenue model not yet established as company is in early research and development stage following recent pre-Series A funding.

DotBio product offering

Product offering

Core offering

DotBio develops multi-functional antibodies based on its proprietary DotBody technology as next-generation cancer therapies. The Singapore-based biopharmaceutical company engineers antibody candidates designed to engage multiple therapeutic targets simultaneously, addressing complex diseases through its preclinical antibody pipeline.

Product overview

DotBio is a Singapore-based biopharmaceutical company focused on developing multifunctional antibodies. The company raised $5.6 million in a pre-Series A funding round in 2023 to support its research and development efforts. No specific named products or modules were identified in the available sources.

Differentiator

Problem solved

Functional benefit

Products and services

  • DotBody Multifunctional Antibody Pipeline

Companies that use DotBio

Customer profile

Ideal customer profiles1 record

DotBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

DotBio partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

DotBio competitors and assessment

Company assessment

Broad incumbents

  • Genmab: Genmab is a leading antibody therapeutics company and the developer of the DuoBody bispecific antibody platform, making it a direct strategic reference point for DotBio's DotBody multifunctional antibody approach.
  • Innovent Biologics: Innovent is a leading Chinese biopharmaceutical company with a portfolio that includes bispecific antibodies (e.g., PD-1-based bispecifics), representing an established Asia-based peer with overlap in multifunctional oncology biologics.

Direct peers

  • Zymeworks: Zymeworks develops multifunctional and bispecific antibody therapeutics using its proprietary platforms (e.g., Azymetric), closely paralleling DotBio's DotBody-based multifunctional antibody strategy in oncology.
  • AbCellera Biologics: AbCellera is an antibody discovery and engineering platform company building multispecific candidates, representing a comparable platform-based business model to DotBio's DotBody technology.
  • Akeso, Inc. Akeso is an Asia-based biopharmaceutical company with a leading pipeline of bispecific and multispecific antibody oncology drugs, making it a strong geographic and modality peer for DotBio.
  • Dragonfly Therapeutics: Dragonfly is developing multispecific antibody-based therapeutics (e.g., its TriNKET platform) for cancer and immune diseases, a close functional analogue to DotBio's multifunctional antibody focus.

Emerging players

  • Adagene: Adagene is an Asia-headquartered (China/Singapore) clinical-stage biotech developing antibody-based therapeutics including bispecifics, an emerging regional peer with comparable modality and geography to DotBio.
  • Cullinan Oncology: Cullinan Oncology is a clinical-stage oncology company developing bispecific antibodies and immune-engaging therapeutics, comparable as a smaller oncology-focused biologics developer.
  • Atreca: Atreca develops antibody-based therapeutics using a proprietary immune repertoire platform, comparable to DotBio as a platform-driven antibody discovery company in oncology.

Others

  • WuXi Biologics: WuXi Biologics is a leading Asia-based biologics contract development and manufacturing organization that supports bispecific/multispecific antibody developers like DotBio with discovery, manufacturing, and IND-enabling services.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

DotBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DotBio leadership team

Management profile

Number of profiles

Profiles1 record

DotBio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DotBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DotBio

What does DotBio do?

DotBio develops multi-functional antibodies based on its proprietary DotBody technology as next-generation cancer therapies. The Singapore-based biopharmaceutical company engineers antibody candidates designed to engage multiple therapeutic targets simultaneously, addressing complex diseases through its preclinical antibody pipeline.

Is DotBio a public or private company?

DotBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was DotBio founded?

DotBio was founded in 2018. It employs 11 to 50 people.

Where is DotBio based?

DotBio is headquartered in Singapore, Singapore, in the Asia region.

How does DotBio make money?

One revenue line is on record: biopharmaceutical Development.

Who are DotBio's main competitors?

Broad incumbents on record are Genmab and Innovent Biologics. Direct peers are Zymeworks, AbCellera Biologics, Akeso, Inc. and Dragonfly Therapeutics. Emerging players are Adagene, Cullinan Oncology and Atreca. WuXi Biologics is listed as an others.

Does DotBio have an API?

No public API is recorded for DotBio.

What industry is DotBio in?

DotBio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals